Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
CagriSema (Cagrilintide + Semaglutide)
Clinical
Research chemical
Summary
Fixed dual research blend combining amylin analog cagrilintide with GLP-1 agonist semaglutide — mirrors the highly effective investigational obesity combination approach.
Categories
Metabolic & Body Comp
Mechanism
Semaglutide: GLP-1R agonism for appetite, gastric emptying, and glycemic control. Cagrilintide: amylin receptor agonism adding satiety, meal-size reduction, and complementary central appetite pathways. Together they hit multiple energy-balance nodes.
Half-life
Both components long-acting (days); weekly research framing
Routes
Subcutaneous injection
Legal / access
Investigational combination concept with strong trial data for the pharmaceutical program. Research vials are not approved CagriSema drug product.
Key risks
- Additive GI side effects (nausea)
- Gallbladder risk class effects
- Muscle-loss with large weight drops
Common claims
- Maximum research weight-loss stack
- Appetite control dual pathway
- Weekly metabolic protocol interest
Select peptide B